Clinical trials: Mental Depression
Depression Bipolar
Study Evaluating Bifeprunox in Bipolar Depression
The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of Bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
- Trial name
- NCT00245973
- Testing
- Bifeprunox
- Where
- 40 sites in United States
- Volunteers
- 380 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Parkinson Disease, Depression
Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
Parkinsons Disease (PD) is caused by a decrease of dopamine in a particular part of the brain. Dopamine is a messenger substance (neurotransmitter) that is used by the cells of the brain (nerve cells) to control and harmonize…
- Trial name
- NCT00297778
- Testing
- Pramipexole
- Where
- 77 sites in Austria, Finland and 11 more
- Volunteers
- 296 people
- Sponsor
- Boehringer Ingelheim
Depressive Disorder, Major
A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder
This study evaluates the efficacy, safety and tolerability of levomilnacipran extended-release (ER) compared with placebo in the prevention of depression relapse in major depressive disorder (MDD).
- Trial name
- NCT02288325
- Testing
- Levomilnacipran ER
- Where
- 47 sites in United States
- Volunteers
- 644 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression
The purpose of this study is to evaluate the efficacy and safety of vortioxetine given as a single intravenous dose of 25 mg at initiation of an oral vortioxetine regimen of 10 mg/day for 7 days
- Trial name
- NCT03766867
- Testing
- Vortioxetine infusion 25 mg, Vortioxetine tablets 10 mg/day
- Where
- 13 sites in Bulgaria, Estonia and 1 more
- Volunteers
- 80 people
- Sponsor
- H. Lundbeck A/S
Fatigue, Low Mood
A Study to Evaluate the Effects of a Beef Liver Supplement on Energy, Mood, and Mental Clarity
This is a randomized, triple-blind, placebo-controlled clinical trial evaluating the effects of the Ancestral Supplements Grass Fed Beef Liver oral supplement on energy, mood, and mental clarity over 12 weeks.
- Conditions
- Fatigue, Low Mood, Mental Clarity, Iron Deficiency
- Trial name
- NCT07892911
- Testing
- Intervention
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ancestral Supplements, LLC
Atopic Dermatitis
A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic
Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24. Description of the: Change in disease activity after 16 and 24 weeks Change in subject and family quality of…
- Trial name
- NCT05527964
- Where
- Czechia
- Volunteers
- 146 people
- Sponsor
- Sanofi
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Major Depressive Disorder
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01371734
- Testing
- Desvenlafaxine Succinate Sustained-Release
- Where
- 42 sites in United States, Chile and 1 more
- Volunteers
- 363 people
- Sponsor
- Pfizer
Major Depressive Disorder
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA-335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD).
- Trial name
- NCT06029426
- Testing
- NMRA-335140
- Where
- 64 sites in United States
- Volunteers
- 383 people
- Sponsor
- Neumora Therapeutics, Inc.
Depressive Disorder, Cancer
Carcinogenicity Study of Bupropion
There is a lack of toxicology data on one bupropion metabolite, and limited literature examining bupropion use and cancer risk. This study evaluates the association between bupropion exposure and the development of cancer of the…
- Trial name
- NCT01077596
- Testing
- Regular bupropion use, Regular SSRI (Selective serotonin reuptake inhibitors) use, Regular TCA (Tricyclic antidepressants) use
- Volunteers
- 50,430 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
- Trial name
- NCT06267846
- Testing
- NBI-1070770
- Where
- 13 sites in United States
- Volunteers
- 73 people
- Sponsor
- Neurocrine Biosciences
Major Depressive Disorder
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major…
- Trial name
- X-NOVA2 (NCT06775379)
- Testing
- Azetukalner
- Where
- 45 sites in United States
- Volunteers
- 450 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Major Depression Disorder
Home tDCS for the Treatment of Major Depression.
The purpose of this multicentric randomized controlled trial is to compare the effectiveness and safety of home-based tDCS for the treatment of major depression versus tDCS treatment in a healthcare centre, and explore the…
- Trial name
- NCT07510880
- Testing
- Accelerated protocol of home Transcranial direct current stimulation, Conventional protocol of home Transcranial direct current stimulation, Conventional protocol of in person Transcranial direct current stimulation
- Where
- 3 sites in Spain
- Volunteers
- 198 people
- Sponsor
- Ionclinics & Deionic SL
Perinatal Depression, Specific Phobia
Maternal Telemental Health Interventions in Response to Covid-19*
The purpose of this study is to assess the effectiveness of a telemental health intervention on the mental health of pregnant women during the COVID-19 crisis in Qatar.
- Conditions
- Perinatal Depression, Specific Phobia, Perinatal Anxiety
- Trial name
- CoronaVirus (NCT04594525)
- Testing
- Low-Intensity Psychosocial Interventions through Telemental health
- Where
- Qatar
- Volunteers
- 58 people
- Sponsor
- Hamad Medical Corporation
Premenstrual Dysphoric Disorder ( PMDD)
YAZ Premenstrual Dysphoric Disorder (PMDD) in China
The purpose of this study is to evaluate the efficacy and safety of YAZ compared to placebo in the treatment of symptoms related to Premenstrual Dysphoric Disorder (PMDD).
- Trial name
- NCT00824187
- Testing
- EE20/DRSP(YAZ, BAY86-5300)
- Where
- 16 sites in China
- Volunteers
- 187 people
- Sponsor
- Bayer
Major Depressive Disorder
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders…
- Trial name
- NCT05061706
- Testing
- Lumateperone
- Where
- 50 sites in United States, Argentina and 5 more
- Volunteers
- 480 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Depressive Disorder, Major
A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder
The purpose of the study is to evaluate the effect of seltorexant, compared to placebo, as an add-on medication to an antidepressant, on next-day driving performance as assessed by the mean difference of standard deviation of…
- Trial name
- NCT04451187
- Testing
- Seltorexant Dose 1, Seltorexant Dose 2, Zopiclone
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Affective Psychosis, Bipolar, Depression, Bipolar
Phase III/Seroquel SR Bipolar Depression Monotherapy - US
The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Depression for 8 weeks.
- Conditions
- Affective Psychosis, Bipolar, Depression, Bipolar, Manic-Depressive Psychosis, Psychoses, Manic-Depressive
- Trial name
- NCT00422214
- Testing
- Quetiapine fumarate (Seroquel) SR
- Where
- 54 sites in United States
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Anxiety Disorders, Major Depressive Disorder
Acquisition and Analysis of Relationships Between Longitudinal Emotional Signals Produced by an Artificial Intelligence Algorithm and Self-questionnaires Used in the Psychiatric Follow-up of Patients With Mood and/or Anxiety Disorders: a Real-Environment Study.
The worldwide prevalence of anxiety and depression increased massively during the pandemic, with a 25% rise in the number of patients suffering from psychological distress.
- Trial name
- EMOACQ-1 (NCT05988840)
- Testing
- Acquisition and analysis of relationships between Longitudinal Emotional Signals produced by a software and Self-questionnaires.
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Emobot
Major Depressive Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
- Trial name
- MOONSTONE (NCT00320268)
- Testing
- Quetiapine fumarate
- Where
- 37 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.